Novartis stämmer Astra Zeneca-bolag för påstått falska budskap

Novartis stämmer Alexion, Astra Zenecas enhet för sällsynta sjukdomar, som man anklagar för att ha lanserat “en falsk och vilseledande marknadsföringskampanj”.

Marie Gårdmark: ”The situation is not satisfactory”

”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration of new products in rare diseases. But will it also work to increase access for all EU patients...

Discover ZEISS ZEN core – now for electron microscopy

Watch the recording of our free webinar.

Rapid development in blood analysis – “Sweden is leading the race”

Thousands of analytical tests using just one single drop of blood. What was revealed as a hoax just a few years ago is now a reality, according to KTH professor...

A mass flow controller that is silent, fast and cost-effective

Portable ventilator breathing devices, bioreactors or the dosing of inert gases all rely on the highest control dynamics. That is exactly what the proportional ...

It couldn’t be simpler

AI-assisted ZEISS Solution inspects implant coatings automatically.

Lundbeck behind the first EU-approved intravenous migraine treatment

A preventive, intravenous treatment for migraines has been approved in the EU for the first time.

Immunterapibolag tar in 339 miljoner

Immunterapibolaget Asgard Therapeutics har tagit in 30 miljoner euro, motsvarande omkring 339 miljoner kronor, i en finanseringsrunda.

Introducing ZEISS arivis Pro 4.2

ZEISS arivis software enhances custom microscopy image analysis.

Enabling 3D Multiplexing Spatial Omics Workflows in Neuroscience

Case study by ZEISS Microscopy.

Study: Popular diabetes treatment is not associated with thyroid cancer

Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by a...

Automated opening and closing of sample vials

From technical requirements to a suitable solution

Karolinska ska bli ett europeiskt powerhouse för ATMP

Karolinska ATMP-centrum har ett enkelt men ambitiöst syfte: korta vägen mellan akademisk upptäckt och klinisk tillämpning. ”Vi önskar att Karolinska i framtiden...

Beta-blockers are often given unnecessarily, a study finds – “This will affect future practice”

Patients who have suffered a minor heart attack do not benefit from beta-blockers, according to a major new study that may change guidelines for cardiac care.

Specific proposals and targets top the universities’ desired priorities

What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Kar...

Ny chefredaktör på Läkartidningen

Åsa Uhlin har utsetts till ny chefredaktör på Läkartidningen efter avgående Pär Sandell.

Aqilions licensdeal gav eko – ”Det var ett litet svenskt biotech som gjorde det”

Var extremt noga med dina vetenskapliga data, men lägg minst lika mycket tid och kraft på affärsutveckling. Det rådet ger Aqilions vd Sarah Fredriksson till bio...

Business Sweden’s new team is rolling out the blue-yellow carpet

According to Business Sweden’s life science team, the combination of substantial medical know-how and an ever-flourishing tech sector is a success factor for Sweden. “It’s a perfect storm, a beneficent, perfect storm,” says Programme Manager Britta...

Looking for greater Nordic cooperation – “We have Norway and Finland in our sights”

How can Medicon Valley Alliance bring the big pharmaceutical companies back to the organisation? Life Science Sweden discussed this topic and others with the cl...

Swedish breakthrough in Alzheimer’s: “We can finally present great data”

Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes ...

The Swedish innovation model: “There is a paradox”

It is often said that Sweden is strong when it comes to innovation, but how well are we turning that innovation into actual medicines?

Björn Arvidsson: “We need robust and recognized ecosystems for continued competitiveness”

“We have idea carriers and excellent innovation opportunities, and now we must invest in creating ecosystems that provide them with even better growth opportuni...

Sepsisbolag tar in kapital

Bioteknikbolaget Aptahem, som utvecklar en behandling mot sepsis, har beslutat om en företrädesemission som kan ge bolaget upp till 34,6 miljoner kronor.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2026)